Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Gynecol Oncol. 2016 Nov 26;144(1):146–152. doi: 10.1016/j.ygyno.2016.11.023

Figure 3.

Figure 3

Cumulative dose response curves of POLE wild type vs POLE-mutated EC cell lines after exposure to Carboplatin (upper panel) and Paclitaxel (lower panel). POLE mutated cell lines are significantly more resistant than POLE wild-type cell lines to Carboplatin (P =0.004), but not to Paclitaxel (P =0.140).